TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8712118
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg alone
Study: 1827000
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 or 5 mg twice daily)
Study: 1827000
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 mg or 25 mg twice daily)
Study: 1827000
Drug: Open-label enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label enalapril (2.5 to 10 mg twice daily)
Study: 17303622
Drug: Diamorphine 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 70 microg ml(‐1) and levobupivacaine (testing interval 0.004%w/v, starting at 0.044%w/v)
Study: 17303622
Drug: Levobupivacaine 0.044%w/v
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.044%w/v (fixed) and diamorphine (testing interval 7 microg ml(‐1), starting at 70 microg ml(‐1))
Study: 17303622
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of diamorphine 69.5 microg ml(‐1) (60.5‐78.5) and levobupivacaine 0.044%w/v (0.039‐0.049)
Study: 15449747
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of low dose morphine with bupivacaine
Study: 11394734
Drug: Lansoprazole-based triple
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole-based triple therapy (LAN 30 mg BID, clarithromycin 500 mg BID, tinidazole 500 mg BID for 1 week, followed by LAN 30 mg BID for 3 weeks)
Study: 11394734
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate-based dual therapy (RBC 400 mg BID plus clarithromycin 500 mg BID for 2 weeks, followed by RBC 400 mg BID for 2 weeks)
Study: 8405743
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection into the abdominal wall (SCA)
Study: 8405743
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection into the thigh (IMT)
Study: 8405743
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection into the thigh (SCT)
Study: 2965461
Drug: anti‐human HBs
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti‐human HBs immunoglobulin (HB Ig) and HB vaccine
Study: 18834319
Drug: 48 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 weeks of pegylated interferon-alpha-2a (180 microg per week) plus ribavirin (1000-1200 mg/day) therapy
Study: 18834319
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of pegylated interferon-alpha-2a (180 microg per week) plus ribavirin (1000-1200 mg/day) therapy
Study: 18834319
Drug: 48 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 weeks of therapy
Study: 18834319
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of therapy
Study: 10676668
Drug: Marine omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine omega-3 fatty acids (4 g/day)
Study: 3953429
Drug: Regular verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular verapamil (80 to 120 mg, 3 times a day)
Study: 3953429
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil (240 to 360 mg once a day)
Study: 27920513
Drug: Discair® inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discair® inhalation (18 μg once-daily)
Study: 27920513
Drug: HandiHaler® inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HandiHaler® inhalation (18 μg once-daily)
Study: 25015763
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg repaglinide, oral, twice daily (group A)
Study: 25015763
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg repaglinide, oral, three times daily (group B)
Study: 15481062
Drug: Oral 6MP
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 6MP plus prednisone (OP)
Study: 15481062
Drug: Intravenous 6MP
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 6MP plus prednisone (IP)
Study: 15481062
Drug: Oral 6MP
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 6MP plus dexamethasone (OD)
Study: 15481062
Drug: Intravenous 6MP
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 6MP plus dexamethasone (ID)
Study: 15481062
Drug: Oral 6MP
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 6MP during consolidation
Study: 15481062
Drug: Intravenous 6MP
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 6MP during consolidation
Study: 10210339
Drug: 4 litres
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 litres of PEG-saline solution and 15 mg of bisacodyl (SELG-4)
Study: 10210339
Drug: 156 mg
Normalized name: menthol 0.156 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 156 mg of sennosides, 15 g of magnesium sulphate, and 2 litres of water (SennMg)
Study: 10210339
Drug: 156 mg
Normalized name: menthol 0.156 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 156 mg of sennosides and 2 litres of PEG-saline solution (SennSELG)
Study: 7887640
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg TAP-144-SR
Study: 7887640
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg TAP-144-SR
Study: 2240542
Drug: Lignocaine‐prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine‐prilocaine cream applied for 5 minutes
Study: 2240542
Drug: Lignocaine‐prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine‐prilocaine cream applied for 60 minutes
Study: 1120946
Drug: Success treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Success treatment for underachievers
Study: 1120946
Drug: Failure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failure treatment for overachievers
Study: 31298712
Drug: Clinics offering
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinics offering medications for opioid use disorders
Study: 28668575
Drug: MenC‐TT vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenC‐TT vaccine
Study: 28647167
Drug: MenACWY‐TT vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐TT vaccine
Study: 20955266
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg once daily
Study: 18828959
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin (EXU)
Study: 14508195
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of irbesartan 150 mg and fosinopril 20 mg
Study: 8829189
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (ceftazidime, amikacine, and metronidazole for 10 days)
Study: 8829189
Drug: Nonantibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonantibiotic treatment
Study: 1463170
Drug: 6 ml
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 ml bupivacaine 0.125%
Study: 1463170
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml bupivacaine 0.125%
Study: 1463170
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml bupivacaine 0.125%
Study: 30700348
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin sodium combined with magnesium sulfate
Study: 29844423
Drug: GCS +
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCS + Low Molecular Weight Heparin (LMWH) (Group B)
Study: 27378312
Drug: Watermelon juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon juice supplementation (300 mL·day−1 for 16 days)
Study: 19294551
Drug: Desire for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desire for effective treatment
Study: 12662366
Drug: Energy prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy prescription diet (n=16)
Study: 31601603
Drug: Antibiotic dispensing
Normalized name: DISPENSING PIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic dispensing from private pharmacies
Study: 29340623
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) - four weekly infusions of 375 mg/m2
Study: 21996047
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 150 mg/d
Study: 21996047
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 60 mg/d
Study: 16705003
Drug: Systemic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroids (Methyl prednisolone 0.5 mg/kg/day i.v. in two divided doses)
Study: 16705003
Drug: Nebulized steroids
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized steroids (Budecort 50 micrograms nebulized every 12 hours)
Study: 1555499
Drug: Hemodilution (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution (group I): six venesections of 400 ml each followed by the injection of 500 ml low-molecular dextran (10%)
Study: 1555499
Drug: Pentoxifylline (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (group II): 400 mg four times daily by mouth after initial intravenous loading
Study: 3924216
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human insulin (1 mU/kg/min)
Study: 3924216
Drug: Insulin antibodies
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin antibodies presence
Study: 3924216
Drug: Insulin action
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin action loss rate
Study: 3924216
Drug: Moderate concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate concentrations of insulin antibodies
Study: 26526713
Drug: Etrolizumab (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab (exact dosage and duration not specified)
Study: 20730362
Drug: HVPC(-) group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVPC(-) group (conventional treatment plus negative polarity HVPC)
Study: 20730362
Drug: HVPC+ group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVPC+ group (conventional treatment plus positive polarity HVPC)
Study: 20730362
Drug: CG (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG (control group with conventional treatment)
Study: 26147635
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1% ointment
Study: 10469709
Drug: 5 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mmol/l taurine
Study: 10469709
Drug: 1 mmol/l
Normalized name: cardiopleg/organ preserv no.1 9 mmol-198 mmol-2 mmol-1 mmol/L PERFUSION BOTTLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mmol/l glutamine
Study: 10469709
Drug: 1 mmol/l
Normalized name: cardiopleg/organ preserv no.1 9 mmol-198 mmol-2 mmol-1 mmol/L PERFUSION BOTTLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mmol/l glutamine and 5 mmol/l taurine
Study: 1913008
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil 6 g/day
Study: 1913008
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil 6 g/day (placebo)
Study: 26234526
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg resveratrol supplementation
Study: 9109102
Drug: D-cycloserine (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (15, 50, and 150 mg)
Study: 28025355
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual (normal wait-list)
Study: 21348810
Drug: Oral levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levosimendan
Study: 16536958
Drug: Perceived patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived patient demand for antibiotics
Study: 11712030
Drug: PDGF gel
Normalized name: PDGF-2
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDGF gel
Study: 28939185
Drug: Antibiotic ointment
Normalized name: CVS Antibiotic Ointment
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic ointment
Study: 8063984
Drug: Intensive, individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive, individualized cognitive therapy (10 sessions over 8 weeks)
Study: 8063984
Drug: Daily gastrointestinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily gastrointestinal (GI) symptom monitoring (8 weeks)
Study: 3194864
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg terbutaline (five puffs)
Study: 25323734
Drug: Taurine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (2 g per day orally, divided into two doses, taken 6 h after chemotherapeutic agents)
Study: 16452592
Drug: Inhaled heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled heparin (50,000 IU, twice daily for 2 weeks)
Study: 31327563
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of supervised primaquine (1·0 mg/kg per day)
Study: 31327563
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of supervised primaquine (0·5 mg/kg per day)
Study: 22924607
Drug: High-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cholecalciferol (4000-100,000 IU per week)
Study: 16042223
Drug: IFNβ‐1a‐Avonex 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ‐1a‐Avonex 30 μg intramuscularly once weekly for six years
Study: 9112170
Drug: Trephination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trephination with scleral auto-implant plug soaked with Mitomycin-C (0.2 mg/ml for 5 minutes)
Study: 28838290
Drug: Modified Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Behavioral Activation Treatment (MBAT) for 8 weeks
Study: 26383577
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (Control)
Study: 26711160
Drug: Dronabinol 20
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronabinol 20 mg three times a day and lofexidine 0.6 mg three times a day
Study: 24853059
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural treatment protocol (CBSPp) with treatment as usual (TAU), 24 sessions
Study: 24853059
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural treatment protocol (CBSPp)
Study: 20931422
Drug: Probiotic-containing yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic-containing yogurt (Bifidobacterium DN-173 010-1010 cfu/g) 125 ml before breakfast for 14 days
Study: 20931422
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (pantoprazole 40 mg b.i.d., amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d. for 14 days)
Study: 12352805
Drug: Protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors (indinavir, saquinavir, ritonavir, nelfinavir)
Study: 9935109
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of IM progesterone given 12 hours before oocyte retrieval
Study: 9935109
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of IM progesterone given on the day of oocyte retrieval
Study: 6160639
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg per day for one week
Study: 30567527
Drug: FOLFOX-4 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX-4 chemotherapy (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, 5-fluorouracil bolus 400 mg/m2 + infusion 600 mg/m2 for 2 days every 3 weeks)
Study: 30567527
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m2 every three weeks)
Study: 18619971
Drug: Vaccine consisting
Normalized name: IMMUNOTHERAPEUTIC VACCINE CONSISTING OF (PAM)2-LYS-SER-SER-GLN-TYR-ILE-LYS-ALA-ASN-SER-LYS-PHE-ILE-GLY-ILE-THR-GLU-ALA-ALA-ALA-PHE-LEU-PRO-SER-ASP-PHE-PHE-PRO-SER-VAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine consisting of recombinant VacA, CagA, and NAP with aluminium hydroxide as an adjuvant
Study: 18619971
Drug: Vaccine consisting
Normalized name: IMMUNOTHERAPEUTIC VACCINE CONSISTING OF (PAM)2-LYS-SER-SER-GLN-TYR-ILE-LYS-ALA-ASN-SER-LYS-PHE-ILE-GLY-ILE-THR-GLU-ALA-ALA-ALA-PHE-LEU-PRO-SER-ASP-PHE-PHE-PRO-SER-VAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine consisting of recombinant VacA, CagA, and NAP
Study: 14671161
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment (6 microg/kg.d)
Study: 8997054
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural administration of fentanyl 33 micrograms/ml with 0.17% bupivacaine
Study: 8997054
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural administration of morphine 0.21 mg/ml with 0.17% bupivacaine
Study: 8997054
Drug: Bolus epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus epidural administration of fentanyl 100 micrograms
Study: 8997054
Drug: Bolus epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus epidural administration of morphine 3 mg
Study: 2581855
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (cyclophosphamide, vincristine and prednisone)
Study: 30476976
Drug: Dapsone therapy
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone therapy for CSU
Study: 25147733
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - ten weekly intervention sessions
Study: 7782724
Drug: Fasting blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting blood glucose (FBG) cut-off value of 6.7 mmol L-1
Study: 7782724
Drug: Fasting blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting blood glucose (FBG) cut-off value of 6.0 mmol L-1
Study: 7782724
Drug: Fasting blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting blood glucose (FBG) cut-off value of 4.8 mmol L-1
Study: 7782724
Drug: Fasting blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting blood glucose (FBG) optimal cut-off value of 5.3 mmol L-1
Study: 7782724
Drug: 2-h oral
Normalized name: dextroamphetamine 2 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-h oral glucose tolerance test (OGTT)
Study: 2371368
Drug: Haloperidol plasma
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol plasma level 2‐13 ng/ml
Study: 2371368
Drug: Haloperidol plasma
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol plasma level 13.1‐24 ng/ml
Study: 2371368
Drug: Haloperidol plasma
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol plasma level 24.1‐35 ng/ml
Study: 1744385
Drug: 0.1 N
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 N HCl infusion
Study: 27415
Drug: Various test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various test solutions (distilled water, 0.9% NaCl, 1.8% NaCl, 3.6% NaCl, 0.1 N HCl, 0.2 N HCl)
Study: 27415
Drug: 0.1 N
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 N HCl infusion with increased rate
Study: 27415
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of intraluminal fluid
Study: 27415
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of bolus injection
Study: 30498908
Drug: Growth factor-based
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth factor-based therapies
Study: 30498908
Drug: Small molecule-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule-based therapies
Study: 27548030
Drug: Community-implemented treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-implemented treatment (CIT)
Study: 15349137
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (66 mg elemental iron)